Loading organizations...
Clinical-stage radiopharmaceutical company developing targeted molecules to deliver radiation to cancer cells precisely.
Alpha-9 Oncology is a clinical-stage biotechnology company based in Boston, Massachusetts, and Vancouver, British Columbia, that develops targeted radiopharmaceuticals to deliver radiation precisely to cancer cells. The organization engineers bespoke molecules for oncology targets, advancing a clinical pipeline of diagnostic imaging agents and therapeutics such as A9-3202 for metastatic melanoma and A9-3408 while minimizing off-target effects on healthy tissue. Operating as a pre-revenue venture-backed entity with a planned headcount of 45 employees, the company has raised over $260 million in total venture funding, including a $75 million Series B in 2022 and a $175 million Series C in 2024. This capital was secured from prominent institutional investors including Lightspeed Venture Partners, Frazier Life Sciences, General Catalyst, RA Capital Management, and OrbiMed. Alpha-9 Oncology was founded in 2019 by François Bénard, Kuo-Shyan Lin, and David Perrin.
Alpha-9 Oncology has raised $175.0M across 1 funding round.
Alpha-9 Oncology has raised $175.0M in total across 1 funding round.
Alpha-9 Oncology has raised $175.0M in total across 1 funding round.
Alpha-9 Oncology's investors include Ascenta Capital, Lightspeed Venture Partners.
Alpha-9 Oncology has raised $175.0M across 1 funding round. Most recently, it raised $175.0M Series C in October 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 23, 2024 | $175.0M Series C | Ascenta Capital, Lightspeed Venture Partners |